Zepbound® Tirzepatide

Zepbound® is an injectable prescription medicine that may help adults with obesity, weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound® should be used with a reduced-calorie diet and increased physical activity.

Zepbound® works differently than other obesity management medications by activating 2 hormone receptors. It reduces appetite and food intake.*

* Hormone receptors of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).

Overall change in body weight after 17 months* in adults without diabetes was a loss of 15.0% (34 lbs) for 5 mg, 19.5% (44 lbs) for 10 mg, 20.9% (48 lbs) for 15 mg, and 3.1% (7 lbs) for placebo. Average starting weights were 226.8 lbs for 5 mg, 233.3 lbs for 10 mg, 232.8 lbs for 15 mg, and 231.0 lbs for placebo.

*Treatment or placebo included a reduced-calorie diet and increased physical activity.

Individual results may vary.
Data collected in a less rigorous study so findings are less certain. Factors beyond studied medications may have contributed to weight loss.

Zepbound is not for cosmetic weight loss.

¶Along with diet and exercise.

**In a 72-week study of adults without diabetes with obesity or overweight and weight-related medical problems, participants on Zepbound MTD (10 mg or 15 mg, the max dose a participant could tolerate) experienced on average a 20.2% (50 Ibs) weight loss compared to an average of 13.7% (33 Ibs) weight loss for participants on Wegovy MTD (1.7 mg or 2.4 mg, the max dose a participant could tolerate). Average starting weights were 248.4 Ibs for Zepbound MTD and 250 Ibs for Wegovy MTD.

MTD=maximum tolerated dose.

Wegovy® is a registered trademark of Novo Nordisk A/S.

Click the button below and complete the form to receive 3 complimentary Fat Burner Shots with your purchase!